COX-2 expression in human breast carcinomas: Correlation with clinicopathological features and prognostic molecular markers

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 7, 2010, Pages 655-664

  Miglietta, Antonella ^a   Toselli, Marina ^b   Ravarino, Nicoletta ^b   Vencia, Walter ^b   Chiecchio, Andrea ^b   Bozzo, Francesca ^a   Motta, Manuela ^b   Torchio, Bruno ^b   Bocca, Claudia ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MAURIZIANO HOSPITAL   (Italy)

Author keywords

Breast cancer; COX 2; Immunohistochemistry; Prognosis

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PTGS2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CORRELATIONAL STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VOLUME; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; GENE EXPRESSION REGULATION; GENETICS; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SECONDARY; UPREGULATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 77953578583     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2010.486792     Document Type: Article

References (35)

1. Amir M, Agarwal HK. Role of COX-2 selective inhibitors for prevention and treatment of cancer. Pharmazie 2005;60:563-570
2. Sheng H, Shao J, Morrow JD, et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58:362-366
3. Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 2004;31:2-11
4. Singh B, Berry JA, Shoher A, et al. COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol 2005;26:1393-1399
5. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000;89:2637-2645
6. Forones NM, Kawamura KY, Segreto HR, et al. Expression of COX-2 in stomach carcinogenesis. J Gastrointest Cancer 2008;39:4-10
7. Ristimäki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-635
8. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000;60:2101-2103
9. Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001;276:18563-18569
10. Barnes N, Haywood P, Flint P, et al. Survivin expression in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer 2006;94:253-258
11. Chow LW, Yip AY, Loo WT, et al. elecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 2008;1:13-17
12. Boland GP, Butt IS, Prasad R, et al. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 2004;90:423-429
13. O'Connor JK, Avent J, Lee RJ, et al. Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy, Int J Radiat Oncol Biol Phys 2004;58:1034-1040
14. Kelly LM, Hill AD, Kennedy S, et al. Lack of prognostic effect of Cox-2 expression in primary breast cancer on short-term follow-up. Eur J Surg Oncol 2003;29:707-710
15. Ranger GS, Jewell A, Thomas V, Mokbel K. Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers. J Surg Oncol 2004;88:100-103
16. Witton CJ, Hawe SJ, Cooke TG, Bartlett JM. Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology 2004;45:47-54
17. Denkert C, Winzer KJ, Müller BM, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 2003;97:2978-2987
18. Costa C, Soares R, Reis-Filho JS, et al. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 2002;55:429-434
19. Leo C, Faber S, Hentschel B, et al. The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue. Ann Diagn Pathol 2006;10:327-332
20. Sobin LH, Wittekind C, editors. TNM classification of malignant tumours. John Wiley & Sons Press, New York; 2002
21. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grades in breast cancer. Experience from a large study with long-term follow-up. Histopathology 1991;19:403-410
22. Buchholz TA, Wazer DE. Molecular biology and genetics of breast cancer development: A clinical perspective. Semin Radiat Oncol 2002;12:285-295
23. Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res 2004;6:109-118
24. Watanabe O, Shimizu T, Imamura H, et al. Expression of cyclooxygenase-2 in malignant and benign breast tumors. Anticancer Res 2003;23:3215-3221
25. Wang D, Dubois RN. Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol 2004;31:64-73
26. Denkert C, Winzer KJ, Hauptmann S. Prognostic impact of cyclooxygenase-2 in breast cancer. Clin Breast Cancer 2004;4:428-433
27. Sivula A, Talvensaari-Mattila A, Lundin J, et al. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat 2005;89:215-220
28. Perrone G, Zagami M, Santini D, et al. COX-2 expression in lobular in situ neoplasia of the breast: correlation with histopathological grading system according to the Tavassoli classification. Histopathology 2007;51:33-39
29. Perrone G, Santini D, Vincenzi B, et al. COX-2 expression in DCIS: correlation with VEGF, Her-2/neu, prognostic molecular markers and clinicopathologic features. Histopathology 2005;46:561-568
30. Lanza-Jacoby S, Burd R, Rosato FE Jr, et al. Effect of simultaneous inhibition of epidermal growth factor receptor and cyclooxygenase-2 in HER-2/neu-positive breast cancer. Clin Cancer Res 2006;12:6161-6169
31. Cho MH, Yoon JH, Jaegal YJ, et al. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to Her-2/neu and p53 protein expression in invasive ductal carcinoma. Breast 2006;15:390-398
32. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 2002;277:18649-18657
33. Shim JY, An HJ, Lee YH, et al. Overexpression of cyclooxygenase-2 is associated with breast carcinoma and its poor prognostic factors. Mod Pathol 2003;16:1199-1204
34. Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy: Preclinical basis, Am J Clin Oncol 2003;26:S66-S69
35. Falandry C, Canney PA, Freyer G, Dirix LY. Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Ann Oncol 2009;20:615-620